SOLID TUMORS

实体瘤

• 批准号: 6290783
• 负责人: LEE J. HELMAN
• 金额: --
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6290783
• 关键词: Ewing's tumor; T lymphocyte; alkylating agents; antigen presenting cell; cancer risk; child (0-11); clinical research; cytotoxicity; dosage; doxorubicin; human subject; human therapy evaluation; insulinlike growth factor; interview; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer vaccine; osteosarcoma; pediatric neoplasm /cancer; rhabdomyosarcoma; sarcoma; somatostatin; somatotropin

We continue to follow patients previously treated on our high-risk sarcoma study. We are currently in the process of developing a new chemotherapy protocol to go along with our immunotherapy studies which are continuing (see Dr. Mackalls annual report. We will be asking a marrow purging study as well as molecular correlation studies. In addition, we have been considering a collaborative study with the University of Minnesota using a stem cell transplant consolidation phase.We have continued a study in osteosarcoma using a long-acting somatostatin compound (OncoLar) in an attempt to determine whether interruption of the GH-IGF-I axis will have salutary effects in patients with recurrent OS based on laboratory and pilot clinical studies previously conducted in our Branch. To date, we have entered 6 patients at 60 mg monthly and 6 patients at 90 mg monthly OncoLar. We have also entered 4 patients on 60 mg of monthly OncoLar plus 20 mg daily tamoxifen. The mean reduction of IGF-I levels was 52% at 60mg and 32% for patients treated at 90 mg, suggesting that there is no advantage to the higher dose of the somatostatin analog. The mean decrease in the group receiving simultaneous tamoxifen awaits accrual of an additional 2 patients. We have not seen any objective responses in this group of heavily pretreated patients to date. The treatment has been very well tolerated with very few grade 3 toxicities. - Ewing's sarcoma family of tumors (ESFT), immunotherapy, osteosarcoma, rhabdomyosarcoma, IGF-I receptor, - Human Subjects: Minor under 18 Years Old & Human Tissues, Fluids, Cells, etc.

我们继续跟踪先前接受过高风险肉瘤研究治疗的患者。我们目前正在开发一种新的化疗方案，以配合我们正在进行的免疫治疗研究（参见 Mackall 博士的年度报告）。我们将要求进行骨髓净化研究以及分子相关性研究。此外，我们一直在考虑与明尼苏达大学进行一项使用干细胞移植巩固阶段的合作研究。我们继续使用长效生长抑素化合物（OncoLar）进行骨肉瘤研究，试图确定是否可以中断骨肉瘤的治疗。根据我们分支机构之前进行的实验室和试点临床研究，GH-IGF-I 轴将对复发性 OS 患者产生有益影响。迄今为止，我们已纳入 6 名每月 60 毫克的患者和 6 名每月 90 毫克的 OncoLar 患者。还对 4 名接受每月 60 毫克 OncoLar 加上每日 20 毫克他莫昔芬的患者进行了研究。IGF-I 水平平均降低了 60 毫克的患者和 32%。 90 mg 治疗，表明较高剂量的生长抑素类似物没有优势。同时接受他莫昔芬治疗组的平均下降有待另外 2 名患者的增加。迄今为止，我们尚未在这组接受过大量治疗的患者中看到任何客观反应。该治疗的耐受性非常好，几乎没有 3 级毒性。 - 尤文氏肉瘤家族肿瘤 (ESFT)、免疫疗法、骨肉瘤、横纹肌肉瘤、IGF-I 受体， - 人类受试者：18 岁以下未成年人和人体组织、液体、细胞等。